Construction of Molecular Diagnostic Marker Models for Pancreatic Cystic Tumors Based on CfDNA Methylation Sequencing and Proteomic Analysis of Pancreatic Cystic Fluid Samples

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy. Participants will Provide post-operative cyst fluid specimens.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subjects are ≥ 18 years old, regardless of gender;

• Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;

• Subjects voluntarily accepted radical resection of pancreatic cystic tumors;

• Subjects or family members voluntarily sign the informed consent form for clinical research.

Locations
Other Locations
China
Changhai Hospital
RECRUITING
Shanghai
Contact Information
Primary
Kaixuan Wang
lizfish@126.com
021-31166666
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2025-07-31
Participants
Target number of participants: 100
Treatments
Mucinous tumour group
Non-mucinous tumour group
Related Therapeutic Areas
Sponsors
Collaborators: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Nanchang University, Oriental Hepatobiliary Surgery Hospital Affiliated to Naval Military Medical University, Zhejiang University, First Affiliated Hospital Xi'an Jiaotong University, West China Hospital, The Second Affiliated Hospital of Baotou Medical College, LanZhou University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Shandong Province Third hospital, First Affiliated Hospital of Guangxi Medical University
Leads: Zhaoshen Li

This content was sourced from clinicaltrials.gov